<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697979</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0713</org_study_id>
    <nct_id>NCT04697979</nct_id>
  </id_info>
  <brief_title>Post-Stroke Medication Relay</brief_title>
  <acronym>REMEDIPA</acronym>
  <official_title>Post-Stroke Medication Relay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior to discharge from hospital and return home, patients managed for ischemic stroke will&#xD;
      receive a pharmaceutical interview to discuss their discharge prescription (indication,&#xD;
      method of administration, precautions, and possible side effects).&#xD;
&#xD;
      Improvements in the use of medications in the community and in hospital follow-up.&#xD;
&#xD;
      Telephone interviews or teleconsultations will make it possible to assess the patient's&#xD;
      knowledge of his or her treatment and to re-explain it if necessary to improve patient&#xD;
      compliance with treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke</measure>
    <time_frame>1 week</time_frame>
    <description>The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.&#xD;
Statistical evaluation by comparative tests at one week versus two months.&#xD;
Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke</measure>
    <time_frame>2 months</time_frame>
    <description>The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.&#xD;
Statistical evaluation by comparative tests at one week versus two months.&#xD;
Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Medication Compliance</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.&#xD;
Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults patients managed in stroke unit following ischemic stroke who benefiting from a&#xD;
        direct return at home.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients managed in stroke unit following ischemic stroke&#xD;
&#xD;
          -  Benefiting from a direct return home&#xD;
&#xD;
          -  Non-opposition to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier DODE, Dr</last_name>
    <phone>04 72 35 71 08</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.dode@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier RIBES, Dr</last_name>
    <phone>04 72 35 71 08</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.ribes@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Neurologie Vasculaire, Unité 201 Hôpital Neurologique Pierre Wertheimer, HCL</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier DODE, Dr</last_name>
      <phone>04 72 35 71 08</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.dode@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Tae-Hee CHO, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

